Drugs / E2082
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03402178 | Dec 2017 → Feb 2020 | — | Eisai Inc. | Terminated | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03686033 | Oct 2018 → Jun 2019 | photosensitive epilepsy | Eisai Inc. | Terminated | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-07-30 | Eisai Inc. | Results Fatality in Phase I Clinical Study of E2082 eisai.com ↗
Eisai Co., Ltd. (“Eisai”) announced that a volunteer subject who took part in a Phase I clinical study for healthy adults in Japan died after completion of dosing study drug in June 2019. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-11-29 | Eisai Inc. | INVESTIGATION REPORT BY MINISTRY OF HEALTH, LABOUR AND WELFARE FOR FATAL CASE IN PHASE I CLINICAL STUDY FOR E2082 eisai.com ↗ |
| 2019-07-30 | Eisai Inc. | Fatality in Phase I Clinical Study of E2082 eisai.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E2082 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03686033 ↗ |
| Route | Oral | “single ascending oral doses of E2082 in healthy Japanese adult and elderly male participants” NCT03402178 ↗ |